SION Sionna Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 2036042 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-55.0%
TTM EPS YoY47.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-39.0%
ROA-36.4%
ROIC (approx.)-44.5%
Asset turnover—
Leverage & solvency
Liabilities / assets8.6%
Debt / equity0.00x
Current ratio13.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.73x
Accruals ratio-10.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $60.26M | $57.29M |
| SG&A expense | $28.72M | $13.27M |
| Operating income | -$88.98M | -$70.56M |
| Income tax | $0 | $0 |
| Net income | -$75.27M | -$61.69M |
| EBITDA | -$88.33M | -$69.89M |
| EPS (basic) | -1.88 | -15.99 |
| EPS (diluted) | -1.88 | -15.99 |
| Weighted avg. shares (diluted) | 39.96M | 3.86M |
| Balance sheet | ||
| Cash & equivalents | $58.45M | $38.75M |
| Current assets | $241.42M | $150.99M |
| PP&E, net | $2.23M | $2.47M |
| Total assets | $325.95M | $185.75M |
| Current liabilities | $11.71M | $10.42M |
| Total liabilities | $19.12M | $19.10M |
| Shareholders' equity | $306.83M | -$163.71M |
| Shares outstanding | 44.72M | 4.72M |
| Cash flow statement | ||
| Operating cash flow | -$66.30M | -$52.79M |
| Capital expenditure | $377,000 | $27,000 |
| Free cash flow | -$66.67M | -$52.81M |
| Investing cash flow | -$118.75M | -$126.91M |
| Financing cash flow | $205.71M | $178.97M |
| Depreciation & amortization | $647,000 | $668,000 |
| Stock-based compensation | $12.07M | $3.71M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.